Tobira Therapeutics 10-Q 29 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 27, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	RGDO
Entity Registrant Name	REGADO BIOSCIENCES INC
Entity Central Index Key	1311596
Current Fiscal Year End Date	-19
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		33,609,212

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$44,460	$51,557
Restricted cash		81
Prepaid expenses	630	827
Other assets	158	1,693
Total current assets	45,248	54,158
Property and equipment, net	11	239
Total assets	45,259	54,397
Current liabilities:
Accounts payable	417	185
Accrued expenses	7,332	6,298
Warrant liability	1	8
Current portion of long-term debt		2,629
Total current liabilities	7,750	9,120
Total liabilities	7,750	9,120
Commitments and contingencies
Stockholders' equity:
Common stock, $0.001 par value; 500,000,000 shares authorized; 33,609,212 shares issued and outstanding at March 31, 2015 and December 31, 2014	34	34
Additional paid-in-capital	232,674	232,502
Accumulated deficit	-220,031	-212,091
Total stockholders' equity	37,509	45,277
Total liabilities and stockholders' equity	45,259	54,397
Series F Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock	$24,832	$24,832

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	33,609,212	33,609,212
Common stock, shares outstanding	33,609,212	33,609,212
Series F Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$1,000	$1,000
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	10,000	10,000
Convertible preferred stock, shares outstanding	10,000	10,000

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Total revenue	$0	$0
Operating expenses:
Research and development	3,653	13,115
General and administrative	4,234	2,549
Total operating expenses	7,887	15,664
Loss from operations	-7,887	-15,664
Other (expense) income:
Interest income	10	3
Interest expense	-63	-187
Total other (expense) income	-53	-184
Net loss	-7,940	-15,848
Deemed dividend related to beneficial conversion feature of Series F convertible preferred stock		-14,840
Net loss attributable to stockholders	-7,940	-30,688
Net loss attributable to preferred stockholders	-446	-163
Net loss attributable to common stockholders - basic and diluted	-7,494	-30,525
Comprehensive loss applicable to all stockholders	($7,940)	($30,688)
Loss per share - basic and diluted	($0.22)	($1.30)
Weighted-average common shares - basic and diluted	33,609,212	23,496,033

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows used in operating activities:
Net loss	($7,940)	($15,848)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	24	24
Amortization of patents and licenses		35
Accrued final bank fee	7	22
Amortization of debt discount	4	24
Amortization of debt issuance costs		8
Change in fair value of warrant liability	-7	51
Stock-based compensation	172	485
Loss on disposal of property and equipment	204
Changes in operating assets and liabilities:
Prepaid expenses	197	-204
Other assets	1,535	561
Other non-current assets		196
Accounts payable	232	-267
Accrued expenses	1,034	1,496
Net cash used in operating activities	-4,538	-13,417
Cash flows used in investing activities:
Change in restricted cash	81	-1,000
Purchase of property and equipment		-47
Patent and license acquisition costs		-140
Net cash provided by (used in) investing activities	81	-1,187
Cash flows from financing activities:
Proceeds from issuance of common stock, net of underwriting discounts and fees		18,800
Payment of offering costs		-99
Repayment of other notes payable	-2,640
Proceeds from issuance of common stock from exercise of options and warrants		53
Net cash (used in) provided by financing activities	-2,640	18,754
Net (decrease) increase in cash and cash equivalents	-7,097	4,150
Cash and cash equivalents, beginning of period	51,557	30,688
Cash and cash equivalents, end of period	44,460	34,838
Supplemental disclosures of cash flow information:
Cash paid for interest	71	82
Supplemental disclosure of non-cash investing and financing activities:
Exchange of common stock for convertible preferred stock, net of issuance costs		24,824
Accrued common stock issuance and offering costs		100
Series F Convertible Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Fair value of Series F Preferred Stock beneficial conversion feature		14,840
Accretion of deemed dividend on Series F Convertible Preferred Stock		($14,840)

Organization_and_Description_o

Organization and Description of Business	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization and Description of Business	1. Organization and Description of Business
	Regado Biosciences, Inc. (the “Company” or “we” or “our” or “us”) is a development stage enterprise incorporated in the State of Delaware on December 19, 2001, operating primarily in Basking Ridge, New Jersey and Durham, North Carolina. We are a biopharmaceutical company that is focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. On August 25, 2014, we announced the permanent termination of enrollment in our REGULATE-PCI phase 3 trial for our lead program, Revolixys™ Kit, formerly known as REG1. The decision was made based on a recommendation from the trial’s Data and Safety Monitoring Board, or DSMB, following their analysis of the data from the first approximately 3,250 patients enrolled in what was intended to be a 13,200-patient trial comparing the safety and efficacy of Revolixys Kit with bivalirudin. Prior to the substantial suspension of our clinical development activities, we were conducting the REGULATE-PCI trial to evaluate Revolixys™ Kit, a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. Revolixys was being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
	In September 2014, we announced that our Board of Directors retained MTS Health Partners, L.P. (“MTS”) and Cowen & Company, LLC, or Cowen, to act as financial advisors in connection with our exploration of potential business alternatives. In addition, the Company, announced the restructuring activities described in Note 8 to the financial statements to reduce costs following the termination of the REGULATE-PCI trial as part of the Company’s decision to focus resources on three principal activities following the termination of the trial: completion of the final closure of the REGULATE-PCI trial and analysis of the unblinded database from the trial, diligence activities associated with thoroughly exploring potential business alternatives, and the Company’s compliance activities associated with being a public company in good regulatory standing. We continue to plan and seek partnerships for preclinical studies of potential new products and maintain and advance our intellectual property portfolio. See Recent Developments for resolution of process.
	On January 14, 2015, the Company entered into an Agreement and Plan of Merger and Reorganization, as amended on January 23, 2015 (the “Merger Agreement”), with Tobira Therapeutics, Inc., a Delaware corporation (“Tobira”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat liver disease, human immunodeficiency virus, fibrosis and inflammation, Landmark Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Company (the “Merger Sub”) and, solely with respect to Section 5.14 of the Merger Agreement, Brent Ahrens, as the agent of Tobira’s stockholders.
	Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including approval of the transaction by the Company’s stockholders and Tobira’s stockholders, the Merger Sub will be merged with and into Tobira (the “Merger”), with Tobira surviving the Merger as a wholly-owned subsidiary of the Company. The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.
	At the effective time of the Merger, but subject to the escrow provisions described below: (a) each outstanding share of Tobira’s common stock will be converted into and exchanged for the number of shares of the Company’s common stock (the “Company Common Stock”) equal to the exchange ratio described below; (b) each outstanding Tobira stock option will be assumed by the Company; and (c) certain warrants to acquire Tobira capital stock will be assumed by the Company.
	Under the exchange ratio formula in the Merger Agreement, immediately after the Merger, but excluding the effect of any financing (as described below), the former Tobira securityholders are expected to own approximately 71% of the aggregate number of shares of the Company Common Stock, and the stockholders of the Company immediately prior to the Merger (the “Company Stockholders”) are expected to own approximately 29% of the aggregate number of shares of the Company Common Stock (on a fully diluted basis). This exchange ratio will be adjusted to the extent the Company’s net cash at closing is greater or less than $33 million.
	Following the Merger, Tobira’s Chief Executive Officer, Laurent Fischer, M.D., will be the Company’s Chief Executive Officer, and the Company’s corporate headquarters will be relocated to 701 Gateway Blvd, Suite 300, South San Francisco, CA 94080. Additionally, following the Merger, the board of directors of the Company will consist of nine seats and will be comprised of six representatives of Tobira and three representatives of the Company, with the Company’s current chairman of the board of directors, Dennis Podlesak, continuing to act as chairman of the board of the Company following the Merger.
	The Merger Agreement contains customary representations, warranties and covenants made by the Company and Tobira, including covenants relating to obtaining the requisite approvals of the stockholders of the Company and Tobira, indemnification of directors and officers, the Company’s and Tobira’s conduct of their respective businesses between the date of signing the Merger Agreement and the closing of the Merger and a covenant by the Company to, following the closing of the Merger, file a registration statement on Form S-3 to register the resale of the shares of Company Common Stock issued pursuant to the Merger Agreement.
	The authorization and issuance of the shares of Company Common Stock in the Merger and in the financing described below, amendments of the Company charter related to changing the name of the Company and a potential nine to one reverse stock split are subject to approval by the Company’s stockholders. The Merger is subject to other customary closing conditions, including, among other things, the accuracy of the representations and warranties, subject to certain materiality qualifications, compliance by the parties with their respective covenants and no law or order preventing the Merger and related transactions.
	The Merger Agreement may be terminated by either party under certain circumstances, including, among others: (i) if the closing has not occurred by the six-month anniversary of the Merger Agreement; (ii) if a court or other governmental entity has issued a final and non-appealable order prohibiting the closing; (iii) if the Company’s or Tobira’s stockholders fail to approve the transaction; (iv) upon a material uncured breach by the other party that would result in a failure of the conditions to the closing; or (v) in the event of a material adverse event. Upon termination of the Merger Agreement for a party’s failure to obtain the approval of its stockholders, such party is obligated to pay the other party a termination fee of $1 million plus reimburse the other party’s fees and expenses up to $250,000. If such party enters into an agreement relating to an Acquisition Transaction (as defined in the Merger Agreement) or consummates an Acquisition Transaction within 12 months following a termination for the failure to obtain stockholder approval, such party is obligated to pay an additional $1 million to the other party. In addition, if the Merger Agreement is terminated due to certain breaches of the Merger Agreement, the breaching party is obligated to reimburse up to $250,000 of the other party’s fees and expenses.
	On March 23, 2015, the Company filed a definitive proxy relating to the Merger Agreement and set its special shareholder meeting date as May 4, 2015.
	Liquidity
	Our financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Operations since inception have consisted primarily of developing and acquiring product technologies and securing financing.
	We are not profitable and do not expect to be profitable in the foreseeable future. We have suffered negative cash flows from operating activities of $4.5 million for the three months ended March 31, 2015. We have an accumulated deficit of approximately $220 million as of March 31, 2015. We have devoted most of our financial resources to research and development, including our preclinical development activities and clinical trials. We have not completed development of any product candidate and we have therefore not generated any revenues from product sales. Since we have ceased our clinical product development activities, we do not expect to have any revenues for the foreseeable future. In September 2014, we implemented a workforce reduction plan described in Note 8 to the financial statements and other cost-cutting measures. Also, we will continue to incur expenses from the wind down of the clinical operations and general and administrative costs associated with running the company. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital. As of March 31, 2015, we had approximately $44.5 million of cash and cash equivalents.
	The accompanying financial statements have been prepared assuming that we will operate as a going concern. We have had negative cash flows from operating activities of $4.5 million for the three months ended March 31, 2015. We will continue to closely monitor and analyze expenses and make adjustments as necessary to prioritize business operations. We have entered into the Merger Agreement with Tobira (see Note 1). Assuming that a transaction involving a potential business alternative is not consummated, we believe that our working capital will be sufficient for us to fund our reduced operations for the foreseeable future.

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	2. Basis of Presentation
	Principles of Consolidation
	In March 2013, we incorporated Regado Biosciences Europe Limited, a wholly owned subsidiary registered in England and Wales, in order to establish a legal presence in the European Union (the “EU”) for the purpose of conducting clinical trials in the EU. Regado Biosciences Europe Limited had no operations during the three months ended March 31, 2015 or 2014. This entity has been dissolved during the quarter ended March 31, 2015.
	The accompanying consolidated financial statements include the accounts of Regado Biosciences, Inc. and its wholly owned subsidiary, Regado Biosciences Europe Limited. There were no significant intercompany accounts or transactions that needed to be eliminated in consolidation. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.
	Unaudited Interim Financial Data
	The accompanying interim consolidated financial statements are unaudited. These unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information under Article 210.10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles, or GAAP, for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2014 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments necessary to state fairly our financial position as of March 31, 2015, the results of our operations for the three months ended March 31, 2015 and 2014, and our cash flows for the three months ended March 31, 2015 and 2014. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full year or any other interim period.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	We consider all interest-bearing investments due on demand and all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents included cash of $590,000 and $1.7 million at March 31, 2015 and December 31, 2014, respectively. Cash and cash equivalents at March 31, 2015 and December 31, 2014 also included investments of $43.9 million and $49.9 million, respectively, in money market funds invested in U.S. Treasury securities with original maturities of less than three months. Cash deposits are held in federally insured financial institutions in the United States of America. We maintain cash in accounts which are in excess of federally insured limits.
	Segment and Geographic Information
	Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one operating segment and all of the Company’s operations were in North America during the three months ended March 31, 2015 and 2014.
	Clinical Trial Supplies
	Historically, we capitalized materials that were to be used in our REGULATE-PCI clinical trial that had an alternative future use in either ongoing or future clinical research or development projects. Clinical trial supplies may comprise material used to manufacture active pharmaceutical ingredients (“API”) used to develop our product candidates, in-process or completed API, in-process or completed unlabeled finished drug product and labeled finished drug product. With the termination of the REGULATE-PCI trial and suspension of clinical development activities we have expensed these supplies.
	As of December 31, 2014 we expensed all clinical trial supplies, therefore, there are no clinical trial supplies included in other current assets as of March 31, 2015.
	Clinical Agreements
	We entered into various clinical trial agreements with academic research organizations (“AROs”) and clinical research organizations (“CROs”) for the planning, management and execution of clinical trials. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. Costs for ARO and CRO contracts are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred; such costs are charged to research and development expense in the accompanying consolidated statements of comprehensive loss. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. Upfront contract signing fees are amortized over the life of the respective contract.
	In general, our ARO and CRO service agreements permit either party to terminate at will plus any non-cancellable expenses that have been entered into by the ARO and CRO on the Company’s behalf. Accordingly, such expenses would be accrued at time of contract termination and any prepaid expenses and unamortized advance payments would be expensed, accordingly.
	All upfront and contract signing costs were applied to outstanding invoices or expensed during the year ended December 31, 2014. There are no prepaid expenses or other non-current assets related to clinical agreements as of March 31, 2015.
	Value Added Taxes
	We were charged value added taxes on purchases, made on the Company’s behalf by a CRO, of certain clinical supplies from manufacturers in foreign jurisdictions. As of December 31, 2014, the Company had recorded $1.2 million as a VAT receivable and $780,000 as a VAT liability in the accompanying consolidated balance sheet within other current assets and accrued expenses. As part of a settlement agreement, it was determined that the VAT refund would be made directly to the CRO (See Note 7). We have written off the related receivable and liability as of March 31, 2015. The difference of $420,000 is included in research and development expenses during the three months ended March 31, 2015.
	Intangible Assets and Impairment of Long-lived Assets
	The Company’s policy is to file patent application(s) to protect technology, inventions and improvements that are considered important to the development of its business. The patent positions of technology companies, including the Company, are uncertain and involve complex legal and factual questions for which important legal principles are largely unresolved. Upon receipt of a patent grant, the respective costs are amortized over the remaining life of the patent.
	We perform a quarterly review of finite-lived identified intangible assets to determine whether facts and circumstances indicate that the useful life is shorter than we had originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess recoverability by comparing the projected undiscounted net cash flows associated with the related assets or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of the carrying amount over the fair value of those assets. If an asset’s useful life is shorter than originally estimated, we accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life. For the year ended December 31, 2014, management determined that the carrying value of the patents was impaired and recognized a full impairment loss of $2.1 million on those assets. There are no intangibles assets as of March 31, 2015. No impairment losses were recognized during the three months ended March 31, 2015 and 2014.
	The Company amortized license agreements over the stated contractual life.
	Research and Development
	Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, license and patent amortization and related impairment, VAT expenses, consultants, central laboratories and clinical research organizations, including costs incurred in connection with our clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include overhead costs related to facilities, depreciation, insurance, and small supplies that are not allocated to specific product candidates or indications. R&D costs are expensed as incurred.
	Stock-based Compensation
	In accordance with FASB Accounting Standards Codification (“ASC”) Topic 718, Stock Compensation, as modified or supplemented, we measure compensation cost for share-based payment awards granted to employees and non-employee directors at fair value using the Black-Scholes option-pricing model. We recognize compensation expense on a straight-line basis over the service period for awards expected to vest. Share-based compensation cost related to share-based payment awards granted to non-employees is adjusted each reporting period for changes in the fair value of our common stock until the measurement date. The measurement date is generally considered to be the date when all services have been rendered or the date that options are fully vested.
	Series F Convertible Preferred Stock
	The Series F convertible preferred stock was deemed to have a beneficial conversion feature (a “BCF”). See Note 9 for further detail regarding the accounting for the Series F convertible preferred stock and this feature.
	Net Loss per Share
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under our stock option plan and warrants.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	3 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	3. Recently Issued Accounting Pronouncements
	In August 2014, FASB issued ASU 2014-15-Presentation of Financial Statements-Going Concern (ASC Subtopic 205-40): “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The update requires management to assess a company’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. All entities are required to apply the new requirements in annual periods ending after December 15, 2016, and interim periods thereafter. Early application is permitted. As such, we are required to adopt these provisions for the annual period ending December 31, 2016. We are currently evaluating the impact of FASB ASU 2014-15 but we do not expect the adoption thereof to have a material effect on the Company’s financial statements.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments
	The following table (in thousands) sets forth our assets and liabilities that were measured at fair value on a recurring basis at March 31, 2015 and at December 31, 2014 by level within the fair value hierarchy. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
		As of March 31, 2015									As of December 31, 2014
	Assets and Liabilities	Quoted Prices			Significant		Significant		Balance as of		Quoted Prices		Significant		Significant		Balance at
		In Active			Other		Unobservable		March 31,		In Active		Other		Unobservable		December 31,
		Markets for			Observable		Inputs		2015		Markets for		Observable		Inputs		2014
		Identical			Inputs		(Level 3)				Identical		Inputs		(Level 3)
		Assets			(Level 2)						Assets		(Level 2)
		(Level 1)									(Level 1)
	Assets:
	Money market funds	$	43,870		$	—	$	—	$	43,870	$	49,856	$	—	$	—	$	49,856
	Total assets at fair value	$	43,870		$	—	$	—	$	43,870	$	49,856	$	—	$	—	$	49,856
	Liabilities:
	Warrant liability	$	—		$	—	$	1	$	1	$	—	$	—	$	8	$	8
	Total liabilities at fair value	$	—		$	—	$	1	$	1	$	—	$	—	$	8	$	8
	The change in the fair value measurement using significant unobservable inputs (Level 3) is summarized below (in thousands):
	Balance at December 31, 2014	$	8
	Change in fair value recorded as interest income		(7	)
	Change in fair value recorded as interest expense		—
	Balance at March 31, 2015	$	1
	The warrant liability represents our allocation of a portion of the proceeds from the May 2013 Comerica Loan (as defined in Note 6). The allocation of the proceeds from the Comerica Loan was based on the fair value of the warrant liability on the date of grant. We accounted for equity contracts not indexed to the issuer’s own stock and not meeting the definition of a derivative as an asset or liability. We utilized the Binomial pricing model to determine the fair value of the warrant liability. We record changes in the fair value of the warrant liability as interest expense or interest income, as applicable.
	We used significant assumptions in estimating the fair value of the warrant liability including the estimated volatility, risk free interest rate, estimated fair value of the preferred shares, and the estimated life of the warrant. These assumptions were used to establish an expected set of cash flows which were probability-weighted and discounted to present value to determine a fair value.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses
	The components of accrued expenses are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Accrued restructuring costs	$	6,720	$	4,591
	Accrued legal and professional services		391		276
	Accrued VAT expenses		—		780
	Accrued interest		—		21
	Accrued compensation and benefits		38		140
	Accrued expenses, other		183		490
	Total accrued expenses	$	7,332	$	6,298

Bank_Debt

Bank Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Bank Debt	6. Bank Debt
	On May 13, 2013, we secured a venture debt loan with Comerica Bank (the “Comerica Loan”). We borrowed $4.5 million (“Tranche One”), and the proceeds of the loan were utilized to repay all amounts due to MidCap Financial SBIC, LP. The Comerica Loan bears interest at Comerica’s Prime Reference Rate (as defined in the Loan Agreement) subject to a floor of 30 day LIBOR plus 250 basis points plus 4.0%, or 7.25% as of March 31, 2015 and December 31, 2014. The terms allow for an interest only period of 15 months, and the remaining principal and interest will be repaid starting September 2014 over a nine-month period (24 months in total), maturing in 2015. As of March 31, 2015, this loan was repaid in its entirety.
	Interest expense recorded related to the Comerica Loan, including changes in fair value of warrants, was approximately $63,000 and $187,000 for the three month periods ending March 31, 2015 and 2014, respectively.
	In connection with the funding of Tranche One, we issued to Comerica a warrant to purchase 156,250 shares of the Series E Preferred Stock at a price of $0.72 per share, or the Warrant Price, subject to adjustment for stock splits, combinations, reclassifications or exchanges and certain dilutive issuances. After giving effect to our IPO and reverse stock split, the warrant was adjusted to a warrant to purchase 9,356 shares of our common stock at a price of $12.02 per share (see Note 4).

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies
	Employment Agreement
	We entered into an employment agreement with our President and Chief Operating Officer which has an effective date of October 2014. The agreement specifies the compensation payable to, and the services to be provided by, the executive. If the agreement should be terminated by us for other than cause, as defined, we are required to pay 12 months of the executive’s base salary and the executive’s target bonus for the year to be paid semi-monthly.
	Clinical Agreements
	We had various clinical trial agreements with AROs and CROs for the planning, management and execution of clinical trials. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. These contracts generally provide for termination on notice (see Note 2—Clinical Agreements). All such contracts have been terminated as of December 31, 2014.
	Milestones and Other Obligations
	Upon the commencement of our REGULATE-PCI trial which occurred in September 2013, we were obligated to make milestone payments of $500,000 to Duke University (“Duke”), and $1.0 million to Archemix Corporation, (“Archemix”). All amounts have been paid. There are no further payments due for milestones and no outstanding obligations as of March 31, 2015.
	We entered into an agreement with MTS where they would advise us in connection with its consideration, evaluation and/or exploration of potential transactions. The fees would be a non-refundable retainer of $100,000 upon execution of the agreement plus a fee equal to $1.5 million upon the closing of the transaction, with $500,000 payable in the form of public company securities. The $100,000 retainer was paid during the year ended December 31, 2014. The $1.5 million payment will be paid if we consummate a transaction, including the pending merger with Tobira. There have been no payments made for the three months ended March 31, 2015.
	We entered into an agreement with Cowen and Company, LLC (“Cowen”) where Cowen has been engaged to act as a financial advisor to us in connection with the proposed merger transaction with Tobira. A cash fee of $500,000 was due when Cowen informed the Board of Directors of the Company that it was prepared to render its first opinion. This amount was due without regard to whether the transaction was consummated. This cash fee was paid during the three months ended March 31, 2015. In the event of a subsequent opinion, Cowen shall be paid $250,000 in common stock of the Company. If the transaction is consummated, Cowen shall be paid a transaction fee at the closing of the transaction of $250,000 payable in common stock.
	Operating Leases
	In April 2014, we entered into a 6-year lease agreement for 18,467 square feet of administrative office space at 106 Allen Road in Basking Ridge, NJ. In February 2015, we entered into an assignment of the lease whereas we assigned all rights to the space to the tenant and they assume all obligations under the lease. As of February 2015, we had remaining minimum lease payments of $2.4 million. The assignee has assumed the minimum lease payments of $2.4 million for a net effect of $0. This assignment does not relieve us from any covenants or obligations under the lease. We incurred expenses of $255,000 related to the assignment of the lease during the three months ended March 31, 2015.
	In May 2013, we entered into a three-year lease agreement for 1,657 square feet of administrative office space in Durham, North Carolina. This lease is current and active.
	Legal Proceedings
	On February 2, 2015, a purported shareholder of the Company filed a putative class-action lawsuit (captioned Maiman v. Regado Biosciences, Inc., Case No. 10606-CB) in the Court of Chancery for the State of Delaware (the “Court”), challenging the proposed stock-for-stock Merger of the Company with Tobira (“Proposed Merger”). On February 25, 2015, a second, related putative class action (captioned Gilboa v. Regado Biosciences, Inc., Case No. 10720-CB) was filed in Delaware Chancery Court challenging the Proposed Merger. The complaints name as defendants: (i) each member of the Company’s Board of Directors, (ii) the Company, (iii) Tobira, and (iv) Landmark Merger Sub Inc. Plaintiffs allege that the Company’s directors breached their fiduciary duties to the Company’s stockholders by, among other things, (a) agreeing to merge the Company with Tobira for inadequate consideration, (b) implementing a process that was distorted by conflicts of interest, and (c) agreeing to certain provisions of the Merger Agreement that are alleged to favor Tobira and deter alternative bids. Plaintiffs also generally allege that the entity defendants aided and abetted the purported breaches of fiduciary duty by the directors. On March 25, 2015, the Court consolidated the two actions and assigned lead counsel for plaintiffs. On March 27, 2015, plaintiffs filed a motion for expedited proceedings and a motion for preliminary injunction. On April 20, 2015, the parties agreed in principle to resolve the litigation (subject to approval by the Court) and signed a memorandum of understanding setting forth the terms of the proposed settlement. On April 23, 2015, as part of the proposed settlement, Regado provided additional disclosures to the Company’s shareholders.
	On March 30, 2015, PAREXEL International, LLC (“PAREXEL”) filed suit against the Company in the United States District Court for the District of Massachusetts alleging breach of contract and breach of the implied covenant of good faith and fair dealing claims, as well as violations of Chapter 93A of the Massachusetts General Laws, arising from the closing out of the parties’ contract for PAREXEL’s services in furtherance of the REGULATE-PCI clinical trial. PAREXEL filed a motion to voluntarily dismiss its lawsuit for lack of subject matter jurisdiction on April 2, 2015, which the court granted on April 6, 2015. Also on April 2, 2015, PAREXEL filed a substantially similar lawsuit in the Superior Court of Massachusetts for Suffolk County seeking $6,543,936 in fees and other expenses relating to the trial. On April 3, 2015, the Company filed a lawsuit against PAREXEL in the Superior Court of Massachusetts for Middlesex County, where PAREXEL is headquarted, seeking, inter alia, a declaration that PAREXEL breached the parties’ agreement in satisfaction of any amounts due PAREXEL following the REGULATE-PCI clinical, and alleging breach of contract and breach of the implied covenant of good faith and fair dealing claims, as well as violations of Chapter 93A of the Massachusetts General Laws. On April 9, 2015, the Company moved to dismiss PAREXEL’s case in Suffolk County and PAREXEL moved to dismiss the Company’s case in Middlesex County.
	On April 22, 2015, Regado and PAREXEL reached a settlement relating to payment for services provided by PAREXEL in furtherance of the REGULATE-PCI trial (the “Trial”). Pursuant to the parties’ agreement, Regado agreed to pay PAREXEL $5,000,000 in full and final payment for PAREXEL’s and any additional costs related to those services. Regado further agreed that PAREXEL will address any issues related to any Value Added Tax applicable to the services and pass-through costs relating to the Trial in the Federal Republic of Germany, and that PAREXEL may keep any refund of VAT paid in Germany which relates to the Trial. Pursuant to the settlement, Regado also agreed to stipulate to the dismissal of a lawsuit relating to the subject matter of the above-mentioned settlement agreement that it filed against PAREXEL in the Superior Court of Massachusetts for Middlesex County on April 3, 2015. PAREXEL also agreed to stipulate to the dismissal of a lawsuit, also relating to the subject matter of the above-mentioned settlement agreement that it filed against Regado in the Superior Court of Massachusetts for Suffolk County on April 2, 2015. As a result of this settlement, the Company recorded a charge to research and development expense of approximately $3.4 million in the first quarter of 2015.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Restructuring	8. Restructuring
	On September 24, 2014, the Company announced a workforce reduction plan to reduce costs following the termination of the REGULATE-PCI trial. Pursuant to the workforce reduction plan, the Company eliminated 88% of the Company’s workforce, or 28 of our 32 full-time employees, across all operational sites. Affected employees were offered separation benefits, including severance payments, and temporary healthcare coverage assistance.
	There was $35,000 and $0 of severance expense incurred for the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015 and December 31, 2014, there was $1.7 million and $2.6 million, respectively, of unpaid severance included in accrued expenses.
	We have accrued $6.7 million and $4.6 million as of March 31, 2015 and December 31, 2014, respectively, in connection with the wind down of various operational activities for the company including severance, final payments and close down expenditures.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity
	Common and Preferred Stock Transactions
	During the first quarter of 2014, we sold 4,000,000 shares of our common stock at a purchase price of $5.00 per share to certain accredited and institutional investors (the “2014 Private Placement”), raising an aggregate of $20.0 million before sales agency fees and offering costs of approximately $1.4 million. In connection with this financing, the Company entered into a securities purchase agreement, pursuant to which it agreed to register the resale of the shares of common stock issued in the financing.
	On March 21, 2014, we entered into an exchange agreement, (“Exchange Agreement”), with Biotechnology Value Fund, LP, Biotechnology Value Fund II, LP and Investment 10, LLC (“the Exchanging Stockholders”) pursuant to which we effected an exchange (“the Exchange”) of the 2,000,000 shares of our common stock purchased by the exchanging stockholders in our 2014 Private Placement for 10,000 shares of newly designated Series F Convertible Preferred Stock (“Series F”) with a stated value of $1,000 per share, each share of which is convertible into 200 shares of our common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting our common stock).
	In April 2014, we consummated an underwritten public offering of 10,000,000 shares of our common stock (the “April 2014 Offering”) at a price of $6.00 per share or $5.64 per share after deducting underwriting discounts and commissions. Upon the underwriters’ exercise of the over-allotment option in connection with this offering, we issued an additional 279,461 shares of common stock resulting in total net proceeds to us of approximately $57.5 million after deducting underwriting discounts of $3.7 million and offering costs of $0.5 million.
	The preferred stock was issued without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act.
	Series F Convertible Preferred Stock Terms
	Pursuant to the terms of the Series F, the exchanging stockholders have the right to convert the Series F into 2,000,000 shares of our common stock, determined by dividing the stated value of $1,000 per share by the conversion price of $5.00 per share, subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting our common stock; provided, however, that the preferred stock cannot be converted by the exchanging stockholders if, after giving effect thereto, the exchanging stockholders would beneficially own more than 9.99% of our common stock, calculated as provided in the certificate of designation establishing the preferred stock, subject to certain exceptions.
	The holders of the preferred stock will not have the right to vote on any matter except to the extent required by Delaware law.
	Series F convertible preferred shares are entitled to dividends in the same form as dividends actually paid on shares of common stock other than dividends in the form of common stock.
	Upon the execution of a fundamental transaction which effects a merger or other change of control transaction of the Company, a holder will have the right to receive, upon any subsequent conversion of a share of Series F (in lieu of conversion shares) for each issuable conversion share, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such fundamental transaction if it had been, immediately prior to such fundamental transaction, the holder of the shares of common stock into which such holder’s shares of Series F is then convertible.
	Accounting for the Series F Convertible Preferred Stock
	Each share of the Series F is convertible into 200 shares of common stock at any time at the option of the holder, subject to adjustment, and the beneficial ownership limitation provision noted above. The Company has recorded the Series F in equity. The initial carrying value of the Series F was $24.8 million. Upon completion of the Exchange, the conversion option of the Series F was immediately exercisable; therefore, the $14.8 million discount related to the BCF was immediately accreted to Series F, resulting in an increase in the carrying value of the Series F by $14.8 million.
	As the Series F are considered participating securities, the Series F participates in the earnings or losses of the Company. Consequently, net losses were adjusted for the deemed distributions relating to the BCF and losses attributable to preferred stockholders to calculate the net loss attributable to common stockholders for the three months period ended March 31, 2015.
	Warrants
	See Note 4 regarding our issuance of a warrant for Series E Preferred Stock in connection with obtaining the Comerica Loan. As of March 31, 2015 and 2014, we had 9,356 warrants outstanding that were exercisable into common shares at a weighted average price of $12.02 per share at the option of the warrant holder. During the three months ended March 31, 2015, there were no warrants exercised. During the three months ended March 31, 2014, warrants for 6,976 shares of common stock were exercised at an exercise price of $0.17.

Stock_Based_Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Based Compensation	10. Stock Based Compensation
	Equity Compensation Plans
	The 2013 Equity Compensation Plan (the “2013 Plan”) adopted by our Board of Directors in May 2013, became effective upon consummation of the IPO in August 2013. There are 6,088,830 common shares authorized for issuance under the 2013 Plan of which 2,485,227 were available as of March 31, 2015. Upon effectiveness of the 2013 Plan, stock options outstanding under the 2004 Equity Compensation Plan (the “2004 Plan”) to acquire 1,406,910 shares of our common stock were assumed under the 2013 Plan, leaving stock options to acquire 34,342 shares of our common stock outstanding under the 2004 Plan. There will be no further awards made under the 2004 Plan.
	The 2013 Plan includes an “evergreen provision” that allows for an annual increase in the number of shares of common stock available for issuance under the 2013 Plan. The annual increase will be added on the first day of each fiscal year starting January 1, 2014, inclusive, and will be equal to five percent of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year as determined by the board of directors (the “Board”). The Board may act prior to the first day of any calendar year, to provide that there shall be no increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year shall be a lesser number of shares of Common Stock than would otherwise occur. On January 1, 2015 another 1,680,461 options became available for grant under this evergreen provision, increasing the number of shares authorized for issuance under the 2013 Plan from 4,408,369 shares at December 31, 2014 to a total of 6,088,830 shares at March 31, 2015.
	Stock Options
	We use the Black-Scholes-Merton option pricing model to determine the fair value of our stock options. The determination of the fair value of stock-based payment awards on the date of grant using an option pricing model is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. These variables include our expected stock price volatility over the term of the awards, risk-free interest rate, actual employee exercise behaviors and expected dividends.
	The following table shows the weighted average assumptions used to value stock options on the date of grant, as follows:
			Three Months Ended March 31,
			2015						2014
			Employee			Non-Employees			Employee			Non-Employees
	Expected stock price volatility			62.35	%		63	%		54.64	%		61	%
	Risk-free interest rate			0.86	%		1.32	%		1.15	%		0.13	%
	Expected life of option (in years)			2.79			4			3.7			1
	Estimated dividend yield			0	%		0	%		0	%		0	%
	Weighted-average grant date fair value per share		$	0.93		$	0.44		$	2.26		$	1.15
	There were 1,470,510 options granted during the three month period ended March 31, 2015.
	Expected stock price volatility was calculated based on the weighted-average of historical information of similar public entities, for a period consistent with the expected life of the option. We will continue to use a weighted-average approach using other similar public entities’ volatility information until our historical volatility is relevant to measure expected volatility for future option grants. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The average expected life was determined based on anticipated exercise strategy and cancellation behavior for employees and non-employee directors. For the three months ended March 31, 2015, a forfeiture rate of 1% and 0% was used for employees and nonemployee directors, respectively. For the three months ended March 31, 2014, a forfeiture rate of 1% and 0% was used for employees and nonemployee directors, respectively. We have not paid and do not anticipate paying cash dividends; therefore, the expected dividend rate was assumed to be 0%.
	The following table summarizes our aggregate Equity Compensation Plan activity:
			Number of			Weighted Average			Weighted Average			Aggregate
			Options			Exercise Price			Contractual Term			Intrinsic Value (1)
									(in years)
	Outstanding – December 31, 2014			3,839,122		$	4.68			6.43		$	50,252
	Granted			1,470,510
	Exercised			—
	Forfeited			(46,415	)
	Expired			(289,882	)
	Outstanding – March 31, 2015			4,973,335		$	3.52			7.66		$	751,487
	Exercisable – March 31, 2015			2,485,227		$	5.27			5.76		$	108,862
	Vested and expected to vest at March 31, 2015			4,959,746		$	5.27			5.76		$	747,979
	-1	Intrinsic value is the excess of the fair value of the underlying common shares as of March 31, 2015 over the weighted-average exercise price. A negative intrinsic value indicates the weighted-average exercise price is greater than the fair value of the underlying common shares as of March 31, 2015.
	-2	The number of stock options expected to vest takes into account an estimate of expected forfeitures.
	The total intrinsic value of options exercised during the three month periods ended March 31, 2015 and March 31, 2014 was $0 and $30,000, respectively.
	Stock-Based Compensation Expense
	In the first quarter of 2015, the Company decided to extend the exercise period of certain awards. The Company accounted for the extension of the exercise period as a modification under modification accounting. The Company valued the old awards immediately prior to the modification and the excess value of the new award over that value is recorded as an incremental expense over the vesting period. Additional stock compensation cost expensed in the three months ended March 31, 2015 related to the modification was immaterial.
	Total stock-based compensation expense recognized based on the total grant date fair value of options vested and expected to vest was approximately $172,000 and $485,000 for the three months ended March 31, 2015 and 2014, respectively. Due to the valuation allowance against our net deferred tax asset, we have never recognized a tax benefit for stock-based compensation.
	As of March 31, 2015, approximately $1.5 million of total unrecognized compensation cost related to unvested share options is expected to be recognized over a weighted-average period of 2.75 years. If the consummation of the Merger is completed in May 2015, as currently expected, 1,413,791 shares will fully vest and 172,533 shares will cease vesting.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes
	We estimate an annual effective tax rate of 0% for the year ending December 31, 2015, as the Company incurred losses for the three months ended March 31, 2015 and are forecasting additional losses through the end of 2015, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2015.
	Due to our history of losses since inception, there is not enough evidence at this time to support that we will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a valuation allowance, since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. Therefore, no federal or state income taxes are expected and none have been recorded as of March 31, 2015. Income taxes have been accounted for using the liability method.

Net_Loss_per_Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share	12. Net Loss per Share
	Basic net loss per share of common stock is computed by dividing the Company’s net loss attributable to its stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed by giving effect to all potentially dilutive securities, including stock options, warrants and convertible preferred stock. Basic and diluted net loss per share of common stock attributable to the Company’s stockholders was the same for all periods presented on the Consolidated Statements of Comprehensive Loss, as the inclusion of all potentially dilutive securities outstanding would have been anti dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss per share are the same for each period presented.
	In March 2014, the Company issued the Series F with a BCF (See Note 9) and recorded a deemed dividend relating to the BCF of $14.8 million for 2014. The Series F participates in earnings or losses of the Company. Consequently, net losses were adjusted for the deemed distribution relating to the BCF and losses attributable to Series F stockholders to calculate the net loss attributable to common stockholders.
	The following table presents the calculation of basic and diluted net loss per share of common stock attributable to the Company’s common stockholders (in thousands, except share and per share data):
		Three Months Ended
		March 31,
		2015			2014
	Net loss per share:
	Numerator:
	Net loss	$	(7,940	)	$	(15,848	)
	Deemed dividend related to the beneficial conversion feature of Series F convertible preferred stock		—			(14,840	)
	Net loss attributable to common stockholders	$	(7,940	)	$	(30,688	)
	Net loss attributable to preferred stockholders	$	(446	)	$	(163	)
	Net loss attributable to common stockholders — basic and diluted	$	(7,494	)	$	(30,525	)
	Denominator:
	Weighted average common shares outstanding, basic and diluted		33,609,212			23,496,033
	Net loss per share attributable to common stockholders, basic and diluted	$	(0.22	)	$	(1.30	)
	For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to our net loss position. Securities that may potentially dilute earnings per share in the future that have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):
		Three months ended
		March 31,
		2015			2014
	Convertible preferred stock		2,000,000			2,000,000
	Common stock options		4,973,335			4,018,449
	Warrants		9,356			9,356
	Total		6,982,691			6,027,805
	As of March 31, 2015 and 2014, we had 9,356 warrants outstanding that were exercisable into common shares at a weighted average price of $12.02 per share at the option of the warrant holder. During the three months ended March 31, 2015, there were no warrants exercised. During the three months ended March 31, 2014, warrants for 6,976 shares of common stock were exercised at an exercise price of $0.17.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events
	The Company evaluated all other events or transactions that occurred after March 31, 2015 up through date the Company issued these financial statements and found no subsequent event that needed to be reported other than the settlement of the litigation described in Note 7.

Organization_and_Description_o1

Organization and Description of Business (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Liquidity	Liquidity
	Our financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Operations since inception have consisted primarily of developing and acquiring product technologies and securing financing.
	We are not profitable and do not expect to be profitable in the foreseeable future. We have suffered negative cash flows from operating activities of $4.5 million for the three months ended March 31, 2015. We have an accumulated deficit of approximately $220 million as of March 31, 2015. We have devoted most of our financial resources to research and development, including our preclinical development activities and clinical trials. We have not completed development of any product candidate and we have therefore not generated any revenues from product sales. Since we have ceased our clinical product development activities, we do not expect to have any revenues for the foreseeable future. In September 2014, we implemented a workforce reduction plan described in Note 8 to the financial statements and other cost-cutting measures. Also, we will continue to incur expenses from the wind down of the clinical operations and general and administrative costs associated with running the company. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital. As of March 31, 2015, we had approximately $44.5 million of cash and cash equivalents.
	The accompanying financial statements have been prepared assuming that we will operate as a going concern. We have had negative cash flows from operating activities of $4.5 million for the three months ended March 31, 2015. We will continue to closely monitor and analyze expenses and make adjustments as necessary to prioritize business operations. We have entered into the Merger Agreement with Tobira (see Note 1). Assuming that a transaction involving a potential business alternative is not consummated, we believe that our working capital will be sufficient for us to fund our reduced operations for the foreseeable future.
Principles of Consolidation	Principles of Consolidation
	In March 2013, we incorporated Regado Biosciences Europe Limited, a wholly owned subsidiary registered in England and Wales, in order to establish a legal presence in the European Union (the “EU”) for the purpose of conducting clinical trials in the EU. Regado Biosciences Europe Limited had no operations during the three months ended March 31, 2015 or 2014. This entity has been dissolved during the quarter ended March 31, 2015.
	The accompanying consolidated financial statements include the accounts of Regado Biosciences, Inc. and its wholly owned subsidiary, Regado Biosciences Europe Limited. There were no significant intercompany accounts or transactions that needed to be eliminated in consolidation. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Financial Data	Unaudited Interim Financial Data
	The accompanying interim consolidated financial statements are unaudited. These unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information under Article 210.10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles, or GAAP, for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2014 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments necessary to state fairly our financial position as of March 31, 2015, the results of our operations for the three months ended March 31, 2015 and 2014, and our cash flows for the three months ended March 31, 2015 and 2014. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full year or any other interim period.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
	We consider all interest-bearing investments due on demand and all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents included cash of $590,000 and $1.7 million at March 31, 2015 and December 31, 2014, respectively. Cash and cash equivalents at March 31, 2015 and December 31, 2014 also included investments of $43.9 million and $49.9 million, respectively, in money market funds invested in U.S. Treasury securities with original maturities of less than three months. Cash deposits are held in federally insured financial institutions in the United States of America. We maintain cash in accounts which are in excess of federally insured limits.
Segment and Geographic Information	Segment and Geographic Information
	Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one operating segment and all of the Company’s operations were in North America during the three months ended March 31, 2015 and 2014.
Clinical Trial Supplies	Clinical Trial Supplies
	Historically, we capitalized materials that were to be used in our REGULATE-PCI clinical trial that had an alternative future use in either ongoing or future clinical research or development projects. Clinical trial supplies may comprise material used to manufacture active pharmaceutical ingredients (“API”) used to develop our product candidates, in-process or completed API, in-process or completed unlabeled finished drug product and labeled finished drug product. With the termination of the REGULATE-PCI trial and suspension of clinical development activities we have expensed these supplies.
	As of December 31, 2014 we expensed all clinical trial supplies, therefore, there are no clinical trial supplies included in other current assets as of March 31, 2015.
Clinical Agreements	Clinical Agreements
	We entered into various clinical trial agreements with academic research organizations (“AROs”) and clinical research organizations (“CROs”) for the planning, management and execution of clinical trials. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. Costs for ARO and CRO contracts are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred; such costs are charged to research and development expense in the accompanying consolidated statements of comprehensive loss. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. Upfront contract signing fees are amortized over the life of the respective contract.
	In general, our ARO and CRO service agreements permit either party to terminate at will plus any non-cancellable expenses that have been entered into by the ARO and CRO on the Company’s behalf. Accordingly, such expenses would be accrued at time of contract termination and any prepaid expenses and unamortized advance payments would be expensed, accordingly.
	All upfront and contract signing costs were applied to outstanding invoices or expensed during the year ended December 31, 2014. There are no prepaid expenses or other non-current assets related to clinical agreements as of March 31, 2015.
Value Added Taxes	Value Added Taxes
	We were charged value added taxes on purchases, made on the Company’s behalf by a CRO, of certain clinical supplies from manufacturers in foreign jurisdictions. As of December 31, 2014, the Company had recorded $1.2 million as a VAT receivable and $780,000 as a VAT liability in the accompanying consolidated balance sheet within other current assets and accrued expenses. As part of a settlement agreement, it was determined that the VAT refund would be made directly to the CRO (See Note 7). We have written off the related receivable and liability as of March 31, 2015. The difference of $420,000 is included in research and development expenses during the three months ended March 31, 2015.
Intangible Assets and Impairment of Long-lived Assets	Intangible Assets and Impairment of Long-lived Assets
	The Company’s policy is to file patent application(s) to protect technology, inventions and improvements that are considered important to the development of its business. The patent positions of technology companies, including the Company, are uncertain and involve complex legal and factual questions for which important legal principles are largely unresolved. Upon receipt of a patent grant, the respective costs are amortized over the remaining life of the patent.
	We perform a quarterly review of finite-lived identified intangible assets to determine whether facts and circumstances indicate that the useful life is shorter than we had originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess recoverability by comparing the projected undiscounted net cash flows associated with the related assets or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of the carrying amount over the fair value of those assets. If an asset’s useful life is shorter than originally estimated, we accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life. For the year ended December 31, 2014, management determined that the carrying value of the patents was impaired and recognized a full impairment loss of $2.1 million on those assets. There are no intangibles assets as of March 31, 2015. No impairment losses were recognized during the three months ended March 31, 2015 and 2014.
	The Company amortized license agreements over the stated contractual life.
Research and Development	Research and Development
	Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, license and patent amortization and related impairment, VAT expenses, consultants, central laboratories and clinical research organizations, including costs incurred in connection with our clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include overhead costs related to facilities, depreciation, insurance, and small supplies that are not allocated to specific product candidates or indications. R&D costs are expensed as incurred.
Stock-based Compensation	Stock-based Compensation
	In accordance with FASB Accounting Standards Codification (“ASC”) Topic 718, Stock Compensation, as modified or supplemented, we measure compensation cost for share-based payment awards granted to employees and non-employee directors at fair value using the Black-Scholes option-pricing model. We recognize compensation expense on a straight-line basis over the service period for awards expected to vest. Share-based compensation cost related to share-based payment awards granted to non-employees is adjusted each reporting period for changes in the fair value of our common stock until the measurement date. The measurement date is generally considered to be the date when all services have been rendered or the date that options are fully vested.
Series F Convertible Preferred Stock	Series F Convertible Preferred Stock
	The Series F convertible preferred stock was deemed to have a beneficial conversion feature (a “BCF”). See Note 9 for further detail regarding the accounting for the Series F convertible preferred stock and this feature.
Net Loss per Share	Net Loss per Share
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under our stock option plan and warrants.
Recently Issued Accounting Pronouncements	In August 2014, FASB issued ASU 2014-15-Presentation of Financial Statements-Going Concern (ASC Subtopic 205-40): “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The update requires management to assess a company’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. All entities are required to apply the new requirements in annual periods ending after December 15, 2016, and interim periods thereafter. Early application is permitted. As such, we are required to adopt these provisions for the annual period ending December 31, 2016. We are currently evaluating the impact of FASB ASU 2014-15 but we do not expect the adoption thereof to have a material effect on the Company’s financial statements.

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on a Recurring Basis	Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
		As of March 31, 2015									As of December 31, 2014
	Assets and Liabilities	Quoted Prices			Significant		Significant		Balance as of		Quoted Prices		Significant		Significant		Balance at
		In Active			Other		Unobservable		March 31,		In Active		Other		Unobservable		December 31,
		Markets for			Observable		Inputs		2015		Markets for		Observable		Inputs		2014
		Identical			Inputs		(Level 3)				Identical		Inputs		(Level 3)
		Assets			(Level 2)						Assets		(Level 2)
		(Level 1)									(Level 1)
	Assets:
	Money market funds	$	43,870		$	—	$	—	$	43,870	$	49,856	$	—	$	—	$	49,856
	Total assets at fair value	$	43,870		$	—	$	—	$	43,870	$	49,856	$	—	$	—	$	49,856
	Liabilities:
	Warrant liability	$	—		$	—	$	1	$	1	$	—	$	—	$	8	$	8
	Total liabilities at fair value	$	—		$	—	$	1	$	1	$	—	$	—	$	8	$	8
Change in Fair Value Measurement Using Significant Unobservable Inputs (Level 3)	The change in the fair value measurement using significant unobservable inputs (Level 3) is summarized below (in thousands):
	Balance at December 31, 2014	$	8
	Change in fair value recorded as interest income		(7	)
	Change in fair value recorded as interest expense		—
	Balance at March 31, 2015	$	1

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Components of Accrued Expenses	The components of accrued expenses are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Accrued restructuring costs	$	6,720	$	4,591
	Accrued legal and professional services		391		276
	Accrued VAT expenses		—		780
	Accrued interest		—		21
	Accrued compensation and benefits		38		140
	Accrued expenses, other		183		490
	Total accrued expenses	$	7,332	$	6,298

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Weighted Average Assumptions Used to Value Stock Options on Date of Grant	The following table shows the weighted average assumptions used to value stock options on the date of grant, as follows:
			Three Months Ended March 31,
			2015						2014
			Employee			Non-Employees			Employee			Non-Employees
	Expected stock price volatility			62.35	%		63	%		54.64	%		61	%
	Risk-free interest rate			0.86	%		1.32	%		1.15	%		0.13	%
	Expected life of option (in years)			2.79			4			3.7			1
	Estimated dividend yield			0	%		0	%		0	%		0	%
	Weighted-average grant date fair value per share		$	0.93		$	0.44		$	2.26		$	1.15
Summary of Aggregate Equity Compensation Plan Activity	The following table summarizes our aggregate Equity Compensation Plan activity:
			Number of			Weighted Average			Weighted Average			Aggregate
			Options			Exercise Price			Contractual Term			Intrinsic Value (1)
									(in years)
	Outstanding – December 31, 2014			3,839,122		$	4.68			6.43		$	50,252
	Granted			1,470,510
	Exercised			—
	Forfeited			(46,415	)
	Expired			(289,882	)
	Outstanding – March 31, 2015			4,973,335		$	3.52			7.66		$	751,487
	Exercisable – March 31, 2015			2,485,227		$	5.27			5.76		$	108,862
	Vested and expected to vest at March 31, 2015			4,959,746		$	5.27			5.76		$	747,979
	-1	Intrinsic value is the excess of the fair value of the underlying common shares as of March 31, 2015 over the weighted-average exercise price. A negative intrinsic value indicates the weighted-average exercise price is greater than the fair value of the underlying common shares as of March 31, 2015.
	-2	The number of stock options expected to vest takes into account an estimate of expected forfeitures.

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Common Share	The following table presents the calculation of basic and diluted net loss per share of common stock attributable to the Company’s common stockholders (in thousands, except share and per share data):
		Three Months Ended
		March 31,
		2015			2014
	Net loss per share:
	Numerator:
	Net loss	$	(7,940	)	$	(15,848	)
	Deemed dividend related to the beneficial conversion feature of Series F convertible preferred stock		—			(14,840	)
	Net loss attributable to common stockholders	$	(7,940	)	$	(30,688	)
	Net loss attributable to preferred stockholders	$	(446	)	$	(163	)
	Net loss attributable to common stockholders — basic and diluted	$	(7,494	)	$	(30,525	)
	Denominator:
	Weighted average common shares outstanding, basic and diluted		33,609,212			23,496,033
	Net loss per share attributable to common stockholders, basic and diluted	$	(0.22	)	$	(1.30	)
Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	Securities that may potentially dilute earnings per share in the future that have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):
		Three months ended
		March 31,
		2015			2014
	Convertible preferred stock		2,000,000			2,000,000
	Common stock options		4,973,335			4,018,449
	Warrants		9,356			9,356
	Total		6,982,691			6,027,805

Organization_and_Description_o2

Organization and Description of Business - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
	Aug. 25, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Aug. 25, 2014	Dec. 31, 2013
	Patient				Patient
Organization And Description Of Business [Line Items]
Number of patients enrolled	3,250				3,250
Number of subjects in Phase 3 trial	13,200
Net cash used in operating activities		($4,538,000)	($13,417,000)
Accumulated deficit		-220,031,000		-212,091,000
Cash and cash equivalents		44,460,000	34,838,000	51,557,000		30,688,000
Merger Agreement [Member]
Organization And Description Of Business [Line Items]
Percentage of ownership in aggregate number of common stock		71.00%
Closing cash balance limit for adjusting exchange ratio		33,000,000
Number of board of directors seats		9
Potential reverse stock split ratio		Nine to one reverse stock split
Potential reverse stock split ratio		0.11
Termination fee obligated to pay in addition to reimbursement fees		1,000,000
Additional termination fees		1,000,000
Merger Agreement [Member] | Company Representatives [Member]
Organization And Description Of Business [Line Items]
Number of board of directors seats		3
Tobira Therapeutics Inc Member | Merger Agreement [Member]
Organization And Description Of Business [Line Items]
Number of board of directors seats		6
Noncontrolling Interest [Member] | Merger Agreement [Member]
Organization And Description Of Business [Line Items]
Percentage of ownership in aggregate number of common stock		29.00%
Maximum [Member] | Merger Agreement [Member]
Organization And Description Of Business [Line Items]
Reimburse fees and expenses		250,000
Termination fees in event of breach		$250,000

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Basis Of Presentation [Line Items]
Highly liquid debt instruments, maturity period	3 months
Cash	$590,000		$1,700,000
Investments	43,900,000		49,900,000
Clinical trial supplies included in other current assets	0
Prepaid expenses related to clinical agreements	0
Other non-current assets related to clinical agreements	0
VAT receivable, current			1,200,000
VAT liability			780,000
Research and development expenses	3,653,000	13,115,000
Impairments of long-lived assets	0	0
Intangibles assets	0
Value Added Taxes [Member]
Basis Of Presentation [Line Items]
Research and development expenses	420,000
Patents [Member]
Basis Of Presentation [Line Items]
Impairment loss			$2,100,000

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Assets
Total assets at fair value	$43,870	$49,856
Liabilities
Total liabilities at fair value	1	8
Warrant Liability [Member]
Liabilities
Total liabilities at fair value	1	8
Money Market Funds [Member]
Assets
Total assets at fair value	43,870	49,856
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets
Total assets at fair value	43,870	49,856
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money Market Funds [Member]
Assets
Total assets at fair value	43,870	49,856
Significant Unobservable Inputs (Level 3) [Member]
Liabilities
Total liabilities at fair value	1	8
Significant Unobservable Inputs (Level 3) [Member] | Warrant Liability [Member]
Liabilities
Total liabilities at fair value	$1	$8

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Change in Fair Value Measurement Using Significant Unobservable Inputs (Level 3) (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Balance at December 31, 2014	$8
Change in fair value recorded as interest income	-7
Change in fair value recorded as interest expense	0
Balance at March 31, 2015	$1

Accrued_Expenses_Components_of

Accrued Expenses - Components of Accrued Expenses (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Accrued restructuring costs	$6,720	$4,591
Accrued legal and professional services	391	276
Accrued VAT expenses		780
Accrued interest		21
Accrued compensation and benefits	38	140
Accrued expenses, other	183	490
Total accrued expenses	$7,332	$6,298

Bank_Debt_Additional_Informati

Bank Debt - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	13-May-13
Series E Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Issuance of warrants to purchase of stock	12.02	12.02
Comerica Bank [Member]
Debt Instrument [Line Items]
Venture debt loan, borrowed amount				$4,500,000
Venture debt loan, LIBOR period	30 days
Venture debt loan, basis points	2.50%
Debt instrument term	24 months
Loan and security agreement, repayment description	The terms allow for an interest only period of 15 months, and the remaining principal and interest will be repaid starting September 2014 over a nine-month period (24 months in total), maturing in 2015.
Venture debt loan, interest period	15 months
Venture debt loan, interest rate added to LIBOR plus basis points	4.00%		4.00%
Venture debt loan, interest rate	7.25%		7.25%
Due period for repayment of principal and interest	9 months
Loan and security agreement, interest expense	$63,000	$187,000
Comerica Bank [Member] | Series E Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Issuance of warrants to purchase of stock	156,250
Warrant price per share	$0.72
Comerica Bank [Member] | Common Class Undefined [Member]
Debt Instrument [Line Items]
Issuance of warrants to purchase of stock	9,356
Warrant price per share	$12.02

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Apr. 30, 2014	31-May-13	Mar. 31, 2015	Apr. 22, 2015	Dec. 31, 2014	Apr. 02, 2015	Feb. 28, 2015
	sqft	sqft
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Outstanding obligations			$0
Area of administrative office	18,467	1,657
Contractual obligation							2,400,000
Minimum Lease payment assumed by the assignee							2,400,000
Operating lease period	6 years	3 years
Net effect to minimum lease payments							0
Operating lease expense			255,000
Subsequent Event [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Litigation settlement amount				5,000,000
MTS [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Non-refundable fees			100,000
Transaction fees			1,500,000
Stock issued for services			500,000
Non-refundable fees paid			0		100,000
Future payment of transaction			1,500,000
Research and Development Expense [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Litigation settlement expense			3,400,000
PAREXEL International [Member] | Subsequent Event [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Fees and other expenses relating to trial						6,543,936
Duke University [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Milestone payments			500,000
Archemix Corporation [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Milestone payments			1,000,000
Cowen and Company, LLC [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Stock issued for services			250,000
Future payment of transaction			250,000
Obligation fee due			$500,000

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
	Sep. 24, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
	Method
Restructuring and Related Activities [Abstract]
Number of full-time employees	32
Number of eliminated employees	28
Percentage of reduction in company's workforce eliminated	88.00%
Severance expense		$35,000	$0
Accrued severance expense		1,700,000		2,600,000
Accrued restructuring costs		$6,720,000		$4,591,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Apr. 30, 2014	Dec. 31, 2014	Mar. 21, 2014
Subsidiary, Sale of Stock [Line Items]
Number of common stock sold	33,609,212			33,609,212
Proceeds from private placement		$20,000,000
Offering costs		1,400,000
Equity exchange par or stated value	$1,000
Conversion of preferred stock into common stock	2,000,000
Proceeds from issuance of common stock	34,000			34,000
Conversion price of common stock	$5
Beneficial ownership for conversion of preferred stock into common stock	9.99%
Series F Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Equity exchange stock received					10,000
Equity exchange par or stated value					$1,000
Conversion of preferred stock into common stock					200
Carrying value of preferred stock	24,832,000			24,832,000
Discount related to beneficial conversion feature	14,800,000
Increase in carrying value of preferred stock	14,800,000
Series E Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding	$9,356	$9,356
Issuance of warrant to purchase of common stock	12.02	12.02
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of warrant to purchase of common stock	0	6,976
Warrant exercised for common stock at an exercise price		$0.17
2014 Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of common stock sold		4,000,000
Common stock price per share		$5
April 2014 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock price per share			$6
Common stock public offering			10,000,000
Common stock price per share after deducting underwriting discounts and commissions			$5.64
Common stock, shares issued			279,461
Proceeds from issuance of common stock			57,500,000
Underwriting discounts			3,700,000
Offering costs			$500,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Equity exchange stock issued					2,000,000

Stock_Based_Compensation_Addit

Stock Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	31-May-15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining stock options outstanding to acquire common stock, assumed under the 2013 plan	4,973,335		3,839,122
Stock options granted	1,470,510
Expected dividend rate	0.00%
Intrinsic value of options exercised	$0	$30,000
Stock-based compensation	172,000	485,000
Shares expected to vest	4,959,746
Total unrecognized compensation related to unvested	$1,500,000
Recognized over a weighted-average period	2 years 9 months
Scenario Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares expected to vest				1,413,791
Shares expected to cease vesting				172,533
Experience Group One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeiture rate	0.00%	0.00%
Experience Group Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeiture rate	1.00%	1.00%
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares authorized for future issuance	6,088,830		4,408,369
Common shares available for grant	2,485,227
Remaining stock options outstanding to acquire common stock, assumed under the 2013 plan	1,406,910
2004 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for grant	0
Stock option to acquire common stock	34,342
Evergreen Provision [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for grant	1,680,461
Percentage of common stock outstanding			5.00%

Stock_Based_Compensation_Summa

Stock Based Compensation - Summary of Weighted Average Assumptions Used to Value Stock Options on Date of Grant (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	62.35%	54.64%
Risk-free interest rate	0.86%	1.15%
Expected life of option (in years)	2 years 9 months 15 days	3 years 8 months 12 days
Estimated dividend yield	0.00%	0.00%
Weighted-average grant date fair value per share	$0.93	$2.26
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	63.00%	61.00%
Risk-free interest rate	1.32%	0.13%
Expected life of option (in years)	4 years	1 year
Estimated dividend yield	0.00%	0.00%
Weighted-average grant date fair value per share	$0.44	$1.15

Stock_Based_Compensation_Summa1

Stock Based Compensation - Summary of Aggregate Equity Compensation Plan Activity (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options, Outstanding, Beginning Balance	3,839,122
Number of Options, Granted	1,470,510
Number of Options, Exercised	0
Number of Options, Forfeited	-46,415
Number of Options, Expired	-289,882
Number of Options, Outstanding, Ending Balance	4,973,335	3,839,122
Number of Options, Exercisable	2,485,227
Number of Options, Vested and expected to vest	4,959,746
Weighted Average Exercise Price, Outstanding, Beginning Balance	$4.68
Weighted Average Exercise Price, Outstanding, Ending Balance	$3.52	$4.68
Weighted Average Exercise Price, Exercisable	$5.27
Weighted Average Exercise Price, Outstanding, Vested and expected to vest	$5.27
Weighted Average Contractual Term, Outstanding	7 years 7 months 28 days	6 years 5 months 5 days
Weighted Average Contractual Term, Exercisable	5 years 9 months 4 days
Weighted Average Contractual Term, Vested and Expected to Vest	5 years 9 months 4 days
Aggregate Intrinsic Value of Stock Options Outstanding, Beginning Balance	$50,252
Aggregate Intrinsic Value of Stock Options Outstanding, Ending Balance	751,487	50,252
Aggregate Intrinsic Value of Stock Options Exercisable	108,862
Aggregate Intrinsic Value of Stock Options Vested and Expected to Vest	$747,979

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income taxes effective tax rate		0.00%
Income taxes recorded	$0
Federal income taxes	0
State income taxes	$0

Net_Loss_per_Share_Additional_

Net Loss per Share - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2015
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Deemed dividend related to beneficial conversion feature of Series F convertible preferred stock	$14,800	$14,840
Series E Convertible Preferred Stock [Member]
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrants outstanding		$9,356	$9,356
Issuance of warrant to purchase of common stock	12.02	12.02	12.02
Common Stock [Member]
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Issuance of warrant to purchase of common stock	6,976	6,976	0
Warrant exercised for common stock at an exercise price	$0.17	$0.17

Net_Loss_per_Share_Calculation

Net Loss per Share - Calculation of Basic and Diluted Net Loss Per Share of Common Stock Attributable to Company's Common Stockholders (Detail) (USD $)	1 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net loss		($7,940)	($15,848)
Deemed dividend related to the beneficial conversion feature of Series F convertible preferred stock	-14,800		-14,840
Net loss attributable to common stockholders		-7,940	-30,688
Net loss attributable to preferred stockholders		-446	-163
Net loss attributable to common stockholders - basic and diluted		($7,494)	($30,525)
Denominator:
Weighted average common shares outstanding, basic and diluted		33,609,212	23,496,033
Net loss per share attributable to common stockholders, basic and diluted		($0.22)	($1.30)

Net_Loss_per_Share_Schedule_of

Net Loss per Share - Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,982,691	6,027,805
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,000,000	2,000,000
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,973,335	4,018,449
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	9,356	9,356